CA2615173C - Sustained release enhanced lipolytic formulation for regional adipose tissue treatment - Google Patents

Sustained release enhanced lipolytic formulation for regional adipose tissue treatment Download PDF

Info

Publication number
CA2615173C
CA2615173C CA2615173A CA2615173A CA2615173C CA 2615173 C CA2615173 C CA 2615173C CA 2615173 A CA2615173 A CA 2615173A CA 2615173 A CA2615173 A CA 2615173A CA 2615173 C CA2615173 C CA 2615173C
Authority
CA
Canada
Prior art keywords
long acting
glucocorticosteroid
beta
receptor agonist
selective beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2615173A
Other languages
English (en)
French (fr)
Other versions
CA2615173A1 (en
Inventor
John Daniel Dobak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEOTHETICS Inc
Original Assignee
Lithera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37669403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2615173(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lithera Inc filed Critical Lithera Inc
Publication of CA2615173A1 publication Critical patent/CA2615173A1/en
Application granted granted Critical
Publication of CA2615173C publication Critical patent/CA2615173C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2615173A 2005-07-14 2006-07-13 Sustained release enhanced lipolytic formulation for regional adipose tissue treatment Expired - Fee Related CA2615173C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US69915505P 2005-07-14 2005-07-14
US60/699,155 2005-07-14
US72953105P 2005-10-24 2005-10-24
US60/729,531 2005-10-24
US73298105P 2005-11-03 2005-11-03
US60/732,981 2005-11-03
PCT/US2006/027405 WO2007011743A2 (en) 2005-07-14 2006-07-13 Sustained release enhanced lipolytic formulation for regional adipose tissue treatment

Publications (2)

Publication Number Publication Date
CA2615173A1 CA2615173A1 (en) 2007-01-25
CA2615173C true CA2615173C (en) 2012-01-03

Family

ID=37669403

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2615173A Expired - Fee Related CA2615173C (en) 2005-07-14 2006-07-13 Sustained release enhanced lipolytic formulation for regional adipose tissue treatment

Country Status (11)

Country Link
US (7) US7829554B2 (enExample)
EP (2) EP1921919B1 (enExample)
JP (3) JP4778053B2 (enExample)
CN (1) CN106075449A (enExample)
AT (1) ATE552032T1 (enExample)
AU (1) AU2006270165B2 (enExample)
BR (1) BRPI0613034A8 (enExample)
CA (1) CA2615173C (enExample)
ES (1) ES2384641T3 (enExample)
PL (1) PL1921919T3 (enExample)
WO (1) WO2007011743A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370498B2 (en) 2005-07-14 2016-06-21 Neothetics, Inc. Methods of using lipolytic formulations for regional adipose tissue treatment

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2884068B1 (fr) * 2005-03-31 2007-07-27 Valeo Equip Electr Moteur Rotor de machine electrique tournante comportant un manchon intermediaire interpose entre l'arbre et les roues polaires et procede de realisation du rotor.
CN101626759B (zh) * 2006-10-17 2014-08-06 利特拉公司 用于治疗甲状腺眼病的组合物和制剂
MX2009004198A (es) * 2006-10-17 2009-10-19 Lithera Inc Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea.
GB2436412A (en) * 2006-11-27 2007-09-26 Cvon Innovations Ltd Authentication of network usage for use with message modifying apparatus
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB2477030A (en) * 2010-01-15 2011-07-20 Lithera Inc Lyophilised forms of fluticasone, salmeterol and combinations thereof
JP5909070B2 (ja) * 2010-10-28 2016-04-26 国立大学法人 東京大学 Ｇｓ共役受容体に対する医薬品候補化合物をスクリーニングする方法
GB2485886A (en) * 2010-11-24 2012-05-30 Lithera Inc Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction
GEP201606551B (en) * 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
EP3834840B8 (en) * 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
NO2753788T3 (enExample) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015006610A1 (en) * 2013-07-11 2015-01-15 Eastern Vision, Ltd. Direct sale and social networking platform and system
AU2014340351B2 (en) 2013-10-21 2020-01-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
CN106999465B (zh) * 2014-10-14 2020-08-14 斯科勒普特有限公司 身体塑形
HRP20251142T1 (hr) 2015-08-28 2025-11-21 Caliway Biopharmaceuticals Co., Ltd. Farmaceutski pripravak koji se koristi za smanjenje lokaliziranih masnoća i uporaba farmaceutskog pripravka
US20170079985A1 (en) * 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
KR20190121699A (ko) * 2018-04-18 2019-10-28 (주)인벤티지랩 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
JP2025510868A (ja) 2022-03-30 2025-04-15 ライニッシェ フリードリッヒ ヴィルヘルムス ウニヴェルジテート ボン ミラベグロン製剤
WO2025073804A1 (en) 2023-10-04 2025-04-10 Rheinische Friedrich-Wilhelms Universität Bonn, Körperschaft Des Öffentlichen Rechts Composition comprising beta-2-adrenergic receptor agonist for transdermal administration

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898330A (en) 1973-08-01 1975-08-05 Squibb & Sons Inc Corticosteroid phosphate salts/neomycin sulfate ophthalmic
JPS58134404U (ja) 1982-03-04 1983-09-09 大成道路株式会社 コンクリ−ト舗装装置
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
JPS59146905A (ja) 1983-02-07 1984-08-23 Nippon Mining Co Ltd 水素製造装置におけるスチ−ム供給量の制御方法
JPS59155313U (ja) 1983-04-02 1984-10-18 山内　真治 家具の組立装置
NZ212204A (en) 1984-06-04 1988-07-28 Merck & Co Inc Growth-promoting compositions containing hydroxylic compounds
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
JPH0696521B2 (ja) * 1986-01-31 1994-11-30 千寿製薬株式会社 眼局所投与用眼圧降下剤
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5314916A (en) * 1993-04-19 1994-05-24 Alcon Laboratories, Inc. B2 adrenegic agonists and use thereof in the treatment of glaucoma
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
GB9512854D0 (en) 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19780476T1 (de) * 1996-05-13 1998-10-15 Seagate Technology Formstrahl-Lasertexturierung von magnetischen Medien
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
JP4335316B2 (ja) 1996-09-19 2009-09-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
TW469832U (en) 1997-03-14 2001-12-21 Astra Ab Inhalation device
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
BR9815470A (pt) * 1997-04-30 2001-10-23 Bridge Pharma Inc Composição e processo usando um eutÈmero
KR100289510B1 (ko) * 1997-05-26 2001-05-02 다니구찌 이찌로오, 기타오카 다카시 티에프티어레이기판및그것을이용한액정표시장치
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
JPH11106334A (ja) 1997-09-30 1999-04-20 Saitama Daiichi Seiyaku Kk 尿失禁治療剤
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
DK1098988T4 (da) * 1998-07-21 2007-09-03 Danisco Födevare
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
WO2001041806A1 (en) 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US6936426B2 (en) 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
KR20030060921A (ko) 2000-11-03 2003-07-16 히스트오테크 에이피에스 조직 블록을 절단하는 장치 및 방법
DE60117858T2 (de) 2000-12-07 2006-11-30 Universiteit Utrecht Holding B.V. Zusammensetzung zur behandlung von entzündlichen erkrankungen
WO2002060410A2 (en) * 2001-01-30 2002-08-08 The Regents Of The University Of Michigan Methods for sustained release local delivery of drugs for ablation of unwanted tissue
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
US6726714B2 (en) * 2001-08-09 2004-04-27 Scimed Life Systems, Inc. Stent delivery system
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
EP1438019A1 (en) 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
US6625078B2 (en) 2002-02-11 2003-09-23 United Memories, Inc. Look-ahead refresh for an integrated circuit memory
ATE418347T1 (de) 2002-02-19 2009-01-15 Resolution Chemicals Ltd Auf lösungsmitteln basierende sterilisation von steroiden
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6643212B1 (en) 2002-04-18 2003-11-04 United Memories, Inc. Simultaneous function dynamic random access memory device technique
US20040028545A1 (en) * 2002-08-06 2004-02-12 Ta-Chin Wang Cylinder assembly for a mini air compressor
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1613266A4 (en) 2003-04-15 2009-05-06 Theraquest Biosciences Llc METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
WO2004103057A2 (en) * 2003-05-15 2004-12-02 The University Of Georgia Research Foundation, Inc. Compositions and methods for inducing adipose tissue cell death
EP1635844A1 (en) 2003-05-22 2006-03-22 ALTANA Pharma AG Salmeterol and ciclesonide combination
SE0302029D0 (sv) 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB2403655A (en) * 2003-07-11 2005-01-12 Cipla Ltd Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
WO2005009375A2 (en) 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US20050075900A1 (en) 2003-10-02 2005-04-07 Arguimbau Vincent C. Method and apparatus for bulk food marking and tracking with supplier rating system
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20050089555A1 (en) 2003-10-24 2005-04-28 Aventis Pharma Deutschland Gmbh Medicinal targeted local lipolysis
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
ES2381672T3 (es) * 2003-11-14 2012-05-30 Senju Pharmaceutical Co., Ltd. Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco
NZ547178A (en) * 2003-11-20 2008-06-30 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birdsusing the R-isomer of Salbutamol
KR100573828B1 (ko) 2003-12-29 2006-04-26 주식회사 하이닉스반도체 셀데이터의 손실을 방지하기 위한 반도체 메모리 소자
US20080270175A1 (en) 2003-12-31 2008-10-30 Klinger Advanced Aesthetics, Inc. Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures
CN1640390A (zh) 2004-01-17 2005-07-20 北京博尔达生物技术开发有限公司 注射用新鱼腥草素钠冻干粉针剂及制备方法
US20050212152A1 (en) 2004-03-23 2005-09-29 Reens Daniel J System and method for humidifying homes and commercial sites
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
WO2006086001A2 (en) 2004-07-20 2006-08-17 Allergan, Inc. Thermographic assessment of clostridial toxin applications
EP1778638A1 (en) 2004-07-21 2007-05-02 Theravance, Inc. Diaryl ether beta2 adrenergic receptor agonists
CN101065110A (zh) 2004-11-24 2007-10-31 柳署弘 水溶胆汁酸制剂的干燥形式：制备及其用途
KR20070104645A (ko) 2005-02-18 2007-10-26 산텐 세이야꾸 가부시키가이샤 스테로이드 화합물의 부작용 경감 또는 회피 방법
WO2006108176A2 (en) 2005-04-08 2006-10-12 The Regents Of The University Of California Wound healing composition
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
CN1706501A (zh) 2005-05-27 2005-12-14 沈阳药科大学 亲脂性药物环糊精包合物的制备方法
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
FR2893845B1 (fr) 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un corticoide et une phase huileuse
CA2631493A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
MX2008012794A (es) 2006-04-03 2008-10-15 Teva Pharma Microparticulas de farmacos.
DE102007026979A1 (de) 2006-10-06 2008-04-10 Friedrich Siller Inhalationsvorrichtung
MX2009004198A (es) 2006-10-17 2009-10-19 Lithera Inc Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea.
US20100063006A1 (en) 2006-11-22 2010-03-11 American Network Of Lipolysis, Llc Compositions and methods to reduce fat and retract skin
CA2680329A1 (en) 2007-04-04 2008-10-16 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
EP2155180B1 (en) 2007-04-24 2016-07-13 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
PT2170348T (pt) 2007-06-22 2016-11-02 Dompé Farm S P A Comprimidos efervescentes para utilização por via inalatória
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
AU2008331928B2 (en) 2007-12-03 2012-08-16 Bridge Pharma, Inc. Use of RR/SR-ractopamine
US20120169732A1 (en) 2008-01-09 2012-07-05 Allergan, Inc. Method for analysis of facial appearance to assist medical procedure
US20130060123A1 (en) 2008-01-09 2013-03-07 Allergan, Inc. Method for determining breast volume to assist medical procedure
KR101184869B1 (ko) 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
US20110230964A1 (en) 2008-10-17 2011-09-22 Allergan, Inc. Prosthetic implant shell
AU2009305625A1 (en) 2008-10-17 2010-04-22 Allergan, Inc. Prosthetic implant shell
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2477030A (en) 2010-01-15 2011-07-20 Lithera Inc Lyophilised forms of fluticasone, salmeterol and combinations thereof
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US20140094662A1 (en) 2012-10-03 2014-04-03 Allergan, Inc. Method of assessing capsular formation and/or contracture
WO2014055895A1 (en) 2012-10-05 2014-04-10 Allergan, Inc. Injectable device and method for sculpting, augmenting or correcting facial features such as the chin
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370498B2 (en) 2005-07-14 2016-06-21 Neothetics, Inc. Methods of using lipolytic formulations for regional adipose tissue treatment

Also Published As

Publication number Publication date
EP1921919A4 (en) 2010-04-14
EP2397034A1 (en) 2011-12-21
WO2007011743A2 (en) 2007-01-25
JP4778053B2 (ja) 2011-09-21
US20120015918A1 (en) 2012-01-19
US9707192B2 (en) 2017-07-18
US20170266137A1 (en) 2017-09-21
BRPI0613034A8 (pt) 2018-01-02
CA2615173A1 (en) 2007-01-25
US9198885B2 (en) 2015-12-01
ES2384641T3 (es) 2012-07-10
US9370498B2 (en) 2016-06-21
US20110105446A1 (en) 2011-05-05
PL1921919T3 (pl) 2012-09-28
EP1921919A2 (en) 2008-05-21
US20070014843A1 (en) 2007-01-18
JP2009501719A (ja) 2009-01-22
JP2011132262A (ja) 2011-07-07
US7829554B2 (en) 2010-11-09
WO2007011743A3 (en) 2007-11-01
AU2006270165B2 (en) 2010-03-11
US8420625B2 (en) 2013-04-16
BRPI0613034A2 (pt) 2013-01-08
ATE552032T1 (de) 2012-04-15
US20120046256A1 (en) 2012-02-23
US20150359760A1 (en) 2015-12-17
JP2014098041A (ja) 2014-05-29
EP1921919B1 (en) 2012-04-04
CN106075449A (zh) 2016-11-09
US9452147B2 (en) 2016-09-27
AU2006270165A1 (en) 2007-01-25
US20140322305A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
US9452147B2 (en) Lipolytic methods
JP2009501719A5 (enExample)
CA2666612C (en) Methods, compositions, and formulations for the treatment of thyroid eye disease
CA2611496C (en) Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
RU2431501C2 (ru) Липолитические составы с пролонгированным высвобождением для локального лечения отложения жировых тканей
HK1161033A (en) Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
CN101252842A (zh) 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
MX2008000570A (es) Formulacion lipolitica mejorada de liberacion sostenida para tratamiento regional de tejido adiposo
HK1121641A (en) Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
AU2014202738A1 (en) Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190715